Four months after first intranasal flunks influenza test, Revelation's second-gen asset misses on efficacy

Revelation Biosciences had big plans for 2022 after going public via a SPAC in January and also raising $7.7 million in PIPE financing later that month, but two trial flops have hit the small cap biotech in recent months.